{"id":67881,"date":"2026-06-10T14:31:45","date_gmt":"2026-06-10T06:31:45","guid":{"rendered":"https:\/\/flcube.com\/?p=67881"},"modified":"2026-06-10T14:31:46","modified_gmt":"2026-06-10T06:31:46","slug":"eli-lilly-secures-fda-approval-for-every-eight-week-ebglyss-regimen-in-atopic-dermatitis-offering-just-six-annual-injections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67881","title":{"rendered":"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved an expanded dosing regimen for <strong>EBGLYSS\u2122 (lebrikizumab-lbkz)<\/strong>, allowing for <strong>one maintenance dose every eight weeks<\/strong> (250 mg\/2 mL single subcutaneous injection) in patients aged <strong>12 years and older<\/strong> weighing at least <strong>88 pounds (40 kg)<\/strong> with <strong>moderate-to-severe atopic dermatitis<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lebrikizumab is a <strong>monoclonal antibody<\/strong> that <strong>selectively targets and neutralizes IL-13<\/strong> with high binding affinity and slow dissociation rate. Previously approved for once-monthly maintenance dosing with demonstrated long-term disease control, the newly approved every-eight-week regimen represents a significant advancement in treatment convenience.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-details\" class=\"wp-block-heading\">Regulatory Approval Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Name<\/strong><\/td><td>EBGLYSS\u2122 (lebrikizumab-lbkz)<\/td><\/tr><tr><td><strong>New Regimen<\/strong><\/td><td>Every 8 weeks (250 mg\/2 mL subcutaneous)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults and children \u226512 years, \u226540 kg<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-severe atopic dermatitis<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Longitudinal exposure-response modeling + Phase 3 ADjoin extension data<\/td><\/tr><tr><td><strong>Key Differentiator<\/strong><\/td><td>Only approved option requiring just 6 annual maintenance injections<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-amp-trial-data\" class=\"wp-block-heading\">Clinical Evidence &amp; Trial Data<\/h2>\n\n\n\n<h3 id=\"h-phase-3-adjoin-long-term-extension-study\" class=\"wp-block-heading\">Phase 3 ADjoin Long-term Extension Study<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Duration<\/strong>: 32-week maintenance phase<\/li>\n\n\n\n<li><strong>Arms<\/strong>: Every-four-weeks vs. every-eight-weeks dosing<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Exposure-response modeling correlation<\/li>\n\n\n\n<li><strong>Secondary Endpoints<\/strong>: Disease control maintenance, safety profile<\/li>\n\n\n\n<li><strong>Key Finding<\/strong>: Every-eight-week regimen maintained durable disease control comparable to monthly dosing<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-treatment-advantages\" class=\"wp-block-heading\">Treatment Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced Injection Burden<\/strong>: 6 injections annually vs. 12 with monthly regimen<\/li>\n\n\n\n<li><strong>No Required Topicals<\/strong>: First biologic approved without mandatory concomitant topical therapy from initiation<\/li>\n\n\n\n<li><strong>Sustained Efficacy<\/strong>: Long-term data demonstrates consistent disease control over extended periods<\/li>\n\n\n\n<li><strong>Convenience Factor<\/strong>: Enhanced patient adherence through less frequent administration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-position-amp-competitive-landscape\" class=\"wp-block-heading\">Market Position &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atopic Dermatitis Prevalence<\/strong>: Affects approximately 27 million Americans, with 10-15% classified as moderate-to-severe<\/li>\n\n\n\n<li><strong>Biologic Competition<\/strong>: Competes with Dupixent (Sanofi\/Regeneron), Adbry (Eli Lilly), and emerging pipeline candidates<\/li>\n\n\n\n<li><strong>Differentiation Strategy<\/strong>:<\/li>\n\n\n\n<li><strong>Dosing Convenience<\/strong>: Fewest annual injections among approved biologics<\/li>\n\n\n\n<li><strong>Topical Independence<\/strong>: Eliminates requirement for concomitant topical corticosteroids<\/li>\n\n\n\n<li><strong>IL-13 Specificity<\/strong>: Highly selective mechanism targeting key inflammatory pathway<\/li>\n\n\n\n<li><strong>Pricing Implications<\/strong>: Potential premium positioning based on convenience and efficacy profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-impact-amp-revenue-outlook\" class=\"wp-block-heading\">Commercial Impact &amp; Revenue Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Launch Timeline<\/strong>: Immediate availability following FDA approval<\/li>\n\n\n\n<li><strong>Market Penetration<\/strong>: Expected to capture share from both existing biologic users and topical-refractory patients<\/li>\n\n\n\n<li><strong>Revenue Contribution<\/strong>: Analysts project peak annual sales of $2-3 billion globally for lebrikizumab franchise<\/li>\n\n\n\n<li><strong>Healthcare Economics<\/strong>: Reduced administration burden may translate to lower overall healthcare utilization costs<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market adoption, competitive dynamics, and revenue projections. Actual results may differ due to market competition, reimbursement challenges, and evolving treatment paradigms.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[199,911,15],"class_list":["post-67881","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-eli-lilly","tag-nyse-lly","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dosing regimen for EBGLYSS\u2122 (lebrikizumab-lbkz), allowing for one maintenance dose every eight weeks (250 mg\/2 mL single subcutaneous injection) in patients aged 12 years and older weighing at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67881\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dosing regimen for EBGLYSS\u2122 (lebrikizumab-lbkz), allowing for one maintenance dose every eight weeks (250 mg\/2 mL single subcutaneous injection) in patients aged 12 years and older weighing at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67881\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T06:31:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T06:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67881#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67881\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections\",\"datePublished\":\"2026-06-10T06:31:45+00:00\",\"dateModified\":\"2026-06-10T06:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67881\"},\"wordCount\":402,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67881#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67881\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67881\",\"name\":\"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-10T06:31:45+00:00\",\"dateModified\":\"2026-06-10T06:31:46+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dosing regimen for EBGLYSS\u2122 (lebrikizumab-lbkz), allowing for one maintenance dose every eight weeks (250 mg\\\/2 mL single subcutaneous injection) in patients aged 12 years and older weighing at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67881#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67881\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67881#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dosing regimen for EBGLYSS\u2122 (lebrikizumab-lbkz), allowing for one maintenance dose every eight weeks (250 mg\/2 mL single subcutaneous injection) in patients aged 12 years and older weighing at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67881","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections","og_description":"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dosing regimen for EBGLYSS\u2122 (lebrikizumab-lbkz), allowing for one maintenance dose every eight weeks (250 mg\/2 mL single subcutaneous injection) in patients aged 12 years and older weighing at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.","og_url":"https:\/\/flcube.com\/?p=67881","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T06:31:45+00:00","article_modified_time":"2026-06-10T06:31:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67881#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67881"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections","datePublished":"2026-06-10T06:31:45+00:00","dateModified":"2026-06-10T06:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67881"},"wordCount":402,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","NYSE: LLY","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67881#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67881","url":"https:\/\/flcube.com\/?p=67881","name":"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-10T06:31:45+00:00","dateModified":"2026-06-10T06:31:46+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dosing regimen for EBGLYSS\u2122 (lebrikizumab-lbkz), allowing for one maintenance dose every eight weeks (250 mg\/2 mL single subcutaneous injection) in patients aged 12 years and older weighing at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67881#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67881"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67881#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Secures FDA Approval for Every-Eight-Week EBGLYSS Regimen in Atopic Dermatitis, Offering Just Six Annual Injections"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67881"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67881\/revisions"}],"predecessor-version":[{"id":67882,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67881\/revisions\/67882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}